Wednesday, September 16, 2026

While Everyone Chases AI, This Casino Giant Quietly Went on Sale: The Case for Las Vegas Sands

Everyone is piling into AI stocks. Meanwhile, one of the world's biggest casino companies has fallen to its lowest price in a year — even though its resorts are still full and it is buying back a huge slice of its own shares. Here's why Las Vegas Sands deserves a second look.

In 2026, almost every conversation about the stock market comes back to one thing: artificial intelligence. Chips, data centers, chatbots. If a company can't spell "AI," investors seem to lose interest. That is exactly why Las Vegas Sands (NYSE: LVS) is interesting. This is a business you can touch. People get on planes, walk into a resort, eat, watch a show, and yes — gamble.…

At writing · LVS USD 42.31
Read more →
● 3 updates — View →
Latest update · Sep 15, 2026
Verdict: The story got safer. The price didn't move much yet.

Chandra Asri Pacific (TPIA): One Day Up 12%, The Next Day Down 13% — Here’s What’s Really Going On

TPIA is a record-earning, fundamentally transformed company trading at a five-year low — and the next twenty days, specifically the MSCI review on June 23, will determine whether this is the buying opportunity of 2026 or the beginning of something much more serious for Indonesia's stock market.

Indonesia’s largest petrochemical company just reported the best quarter in its history. Its stock is near a five-year low. And the next three weeks could decide everything. If you’ve been watching PT Chandra Asri Pacific (TPIA) this week, you’ve seen one of the most dramatic two-day reversals on the Jakarta exchange in recent memory. On Tuesday, June 2, the stock surged 12% to…

At writing · TPIA Rp 1,615
Read more →
● 2 updates — View →
Latest update · Sep 15, 2026
Current price: $28.81. The revenue story is real. The profit story is not. We're taking 4% and walking away — here's everything that happened in three months.

The Case for Hims & Hers Health: Why the Market is Wrong About the GLP-1 Shakeout

Hims & Hers is an incredibly resilient, cash-rich digital health leader that the market has fundamentally mispriced at under 2.0x forward revenues due to a short-sighted overreaction to temporary GLP-1 compounding regulations.

Turning Regulatory Turbulence into an Asymmetric Buying Opportunity: The Case for Hims & Hers Health The world of growth investing rarely offers second chances. When a hyper-growth company experiences a sharp 60% drawdown from its market highs, the investing community often reacts with panic rather than analytical curiosity. This is exactly what is happening with Hims & Hers He…

At writing · HIMS USD 27.25
Read more →